Erratum: Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (Cancer Cell (2018) 33(5) (853–861.e4), (S1535610818301727) (10.1016/j.ccell.2018.04.001));Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell

Volumn 33, Issue 5, 2018, Pages 853-861.e4

  Hellmann, Matthew D ^a   Callahan, Margaret K ^a   Awad, Mark M ^b   Calvo, Emiliano ^c   Ascierto, Paolo A ^d   Atmaca, Akin ^e   Rizvi, Naiyer A ^f   Hirsch, Fred R ^g   Selvaggi, Giovanni ^h   Szustakowski, Joseph D ^h   Sasson, Ariella ^h   Golhar, Ryan ^h   Vitazka, Patrik ^h   Chang, Han ^h   Geese, William J ^h   Antonia, Scott J ⁱ  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e KRANKENHAUS NORDWEST   (Germany)

^f Department of Medicine   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

biomarkers; clinical trial; CTLA 4; immunotherapy; ipilimumab; nivolumab; PD 1; small cell lung cancer; tumor mutation burden

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMALL CELL LUNG CANCER; SOMATIC MUTATION; SURVIVAL RATE; WHOLE EXOME SEQUENCING; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IPILIMUMAB; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NIVOLUMAB; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; TUMOR BURDEN; WHOLE EXOME SEQUENCING;

EID: 85045874395     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2019.01.011     Document Type: Erratum

References (33)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Alvarado-Luna, G., Morales-Espinosa, D., Treatment for small cell lung cancer, where are we now?—a review. Transl. Lung Cancer Res. 5 (2016), 26–38.
3. Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., Jäger, D., Pietanza, M.C., Le, D.T., de Braud, F., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (2016), 883–895.
4. Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., Wooster, R., The COSMIC (catalogue of somatic mutations in cancer) database and website. Br. J. Cancer 91 (2004), 355–358.
5. Byers, L.A., Rudin, C.M., Small cell lung cancer: where do we go from here?. Cancer 121 (2015), 664–672.
6. Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciuleanu, T.E., Badin, F., et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N. Engl. J. Med. 376 (2017), 2415–2426.
7. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
8. Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., Ruden, D.M., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6 (2012), 80–92.
9. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
10. Fisher, S., Barry, A., Abreu, J., Minie, B., Nolan, J., Delorey, T.M., Young, G., Fennell, T.J., Allen, A., Ambrogio, L., et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol., 12, 2011, R1.
11. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
12. Galsky, M.D., Saci, A., Szabo, P.M., Azrilevich, A., Horak, C., Lambert, A., Siefker-Radtke, A., Necchi, A., Sharma, P., Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase II CheckMate 275 study. [abstract 848PD] Ann. Oncol. 28:suppl 5 (2017), v295–v329.
13. Gazdar, A.F., Bunn, P.A., Minna, J.D., Small-cell lung cancer: what we know, what we need to know and the path forward. Nat. Rev. Cancer 17 (2017), 725–737.
14. George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015), 47–53.
15. Hellmann, M.D., Antonia, S.J., Ponce, S., Ott, P.A., Calvo, E., Taylor, M., Ready, N., Hann, C.L., De Braud, F., Eder, J.P., et al. Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and updated analyses from the CheckMate 032 trial. [abstract MA09.05] J. Thorac. Oncol. 12 (2016), S393–S394.
16. Hellmann, M.D., Nathanson, T., Rizvi, H., Creelan, B.C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J.B., Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer. Cancer Cell, 2018, 10.1016/j.ccell.2018.03.018.
17. Hellmann, M.D., Ott, P.A., Zugazagoitia, J., Ready, N.E., Hann, C.L., De Braud, F.G., Antonia, S.J., Ascierto, P.A., Moreno, V., Atmaca, A., et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. [abstract 8503] J. Clin. Oncol., 35(suppl 15), 2017, 8503.
18. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N. Engl. J. Med. 359 (2008), 1367–1380.
19. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
20. Li, H., Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv, 2013 1303.3997v1 [q-bio.GN].
21. Mills, R.E., Luttig, C.T., Larkins, C.E., Beauchamp, A., Tsui, C., Pittard, W.S., Devine, S.E., An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res. 16 (2006), 1182–1190.
22. National Comprehensive Cancer Network (2017). Clinical practice guidelines in Oncology. Small cell lung cancer. Version 1.2018. https://www.nccn.org/professionals/physician_gls/default.aspx.
23. Peifer, M., Fernández-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44 (2012), 1104–1110.
24. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
25. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
26. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., O'Donnell, P.H., Balmanoukian, A., Loriot, Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
27. Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, E.A., Guan, Y., Shin, J., Guillory, J., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44 (2012), 1111–1116.
28. Saunders, C.T., Wong, W.S., Swamy, S., Becq, J., Murray, L.J., Cheetham, R.K., Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28 (2012), 1811–1817.
29. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
30. Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J.L., Wong, Y.N.S., Rowan, A., Kanu, N., Al Bakir, M., et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18 (2017), 1009–1021.
31. Wang, P.P., Parker, W.T., Branford, S., Schreiber, A.W., BAM-matcher: a tool for rapid NGS sample matching. Bioinformatics 32 (2016), 2699–2701.
32. Weber, J.A., Aldana, R., Gallagher, B.D., Edwards, J.S., Sentieon DNA pipeline for variant detection - software-only solution, over 20× faster than GATK 3.3 with identical results. PeerJ PrePrints, 4, 2016, e1672.
33. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.